Australian journal of general practice · 2025
Inequities in COVID-19 antiviral dispensation in Victoria, Australia: A retrospective cohort study using linked data.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Robinson Elizabeth J, Manoharan Lakshmi, Cowie Benjamin C, Lister David M
Аннотация
BACKGROUND AND OBJECTIVES: Oral antiviral therapies are recommended for treatment of COVID-19 in people vulnerable to severe outcomes. This study examined COVID-19 antiviral dispensation and incidence of severe outcomes among eligible Victorians by socioeconomic status and cultural and linguistic diversity.
METHOD: A retrospective analysis was conducted using linked population data. Dispensation of COVID-19 antiviral treatment (molnupiravir or nirmatrelvir/ritonavir) is described, stratified by socioeconomic and culturally and linguistically diverse (CALD) status between 1 January and 30 June 2023 in Victorian residents aged ≥70 years. Rates of severe COVID-19 outcomes (hospitalisation or death) were also calculated from 1 November 2022 to 30 April 2023.
RESULTS: Victorians living in areas of increasing socioeconomic disadvantage had steadily reduced COVID-19 antiviral dispensation in both CALD and non-CALD groups, with lower rates in CALD groups across all socioeconomic levels. The rate of severe COVID-19 outcomes showed the opposite trend.
DISCUSSION: This analysis suggests that treatment access and outcomes are inequitable in Victorians eligible for COVID-19 antivirals. Increasing equity is a public health imperative.
METHOD: A retrospective analysis was conducted using linked population data. Dispensation of COVID-19 antiviral treatment (molnupiravir or nirmatrelvir/ritonavir) is described, stratified by socioeconomic and culturally and linguistically diverse (CALD) status between 1 January and 30 June 2023 in Victorian residents aged ≥70 years. Rates of severe COVID-19 outcomes (hospitalisation or death) were also calculated from 1 November 2022 to 30 April 2023.
RESULTS: Victorians living in areas of increasing socioeconomic disadvantage had steadily reduced COVID-19 antiviral dispensation in both CALD and non-CALD groups, with lower rates in CALD groups across all socioeconomic levels. The rate of severe COVID-19 outcomes showed the opposite trend.
DISCUSSION: This analysis suggests that treatment access and outcomes are inequitable in Victorians eligible for COVID-19 antivirals. Increasing equity is a public health imperative.